Safety trial of a new targeted therapy for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug, NRT6020, that targets a protein called FAP found on many solid tumors. It aims to see if the drug is safe and how it works in people with advanced solid tumors that have not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old
- You must have an advanced solid tumor that has been confirmed by a biopsy or other test
- You must have at least one tumor that can be measured on a scan
- You must have good organ function and be able to care for yourself (ECOG score of 0 or 1)
- You must not have brain tumors or brain metastases
- You must agree to use effective birth control during the trial and for 12 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new radioactive drug called 68Ga/177Lu-BRP-020063 in people with advanced solid tumors, especially bladder or breast cancer. The drug seeks out Nectin-4 on cancer cells, helping doctors see and potentially treat the tumors. The goal is to check that the drug is safe and tolerable.
This trial tests how safe and effective a targeted radiation medicine (177Lu-FAP-2286) is for people with advanced solid cancers that have limited treatment options. It may help by delivering radiation directly to cancer-related targets and shrinking tumors.
This trial tests an investigational drug called [177Lu]Lu-XT117, which delivers a small dose of radiation directly to cancer cells that have a specific protein called FAP. It is for people with advanced solid tumors who have run out of standard treatment options or cannot tolerate them.
This trial tests an experimental drug that targets tumors with a special protein detected by a PET scan. It may help treat certain cancers like breast, head and neck, pancreatic, or brain cancers that have grown despite prior treatment.
This trial is testing an investigational drug called 177Lu-FAP-VG1 for people with advanced solid tumors that have stopped responding to standard therapy. The drug is a type of radiation therapy that targets a protein called FAP, which is found on many cancer cells, to try to shrink the tumor and slow the cancer's growth.
This trial tests a special imaging technique that may help doctors see and stage solid tumors more precisely. It uses a targeted radioactive tracer to highlight cancer cells during PET and SPECT scans, which could help plan better treatment.
Hear when a new Solid Tumor Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.